AICAR Research Compound Overview for AMPK Research

In this AICAR Research Compound Overview, AICAR refers to the small-molecule research compound also indexed as acadesine or AICA-riboside, not to a peptide sequence. Published laboratory literature uses AICAR as a tool compound for interrogating AMP-activated protein kinase signaling in intact cells and related energy-sensing biology. For qualified research buyers, the practical questions are identity, mechanism, evidence limits, and documentation quality in a research-use-only setting. [1][2][3]

Fast Answer

What AICAR Is

AICAR is most accurately described in an RUO article as a small-molecule research compound. PubChem indexes the compound under the name acadesine, and ChEMBL lists ACADESINE as a small molecule with molecular formula C9H14N4O5 and molecular weight 258.23. That chemical framing is important because AICAR discussions should center on compound identity, molecular formula, and pathway biology rather than peptide-sequence terminology. [1][2]

Published literature most often introduces AICAR as a pharmacologic AMPK probe in intact-cell research. In practice, that means the core educational question is not “what does AICAR do” in a broad consumer sense, but “what does AICAR let researchers test” in defined laboratory systems. The classic 1995 paper from Corton and colleagues is still foundational because it framed AICAR as a way to activate AMP-activated protein kinase in intact cells and connect that activation to downstream biochemical changes. [3]

Key identifiers

• Common names: AICAR, acadesine, and AICA-riboside all appear in reference databases tied to the same parent small molecule. [1][2]
• Compound class: ChEMBL classifies ACADESINE as a small molecule rather than a peptide. [2]
• Core identity markers: the database-listed molecular formula is C9H14N4O5, and the database-listed molecular weight is 258.23. [1][2]
• Primary research framing: the literature uses AICAR as a pathway probe in AMPK signaling studies performed in intact research systems. [3]

How AICAR Activates AMPK in Research Settings

AMPK is a heterotrimeric energy sensor composed of alpha, beta, and gamma subunits. The gamma subunit binds adenine nucleotides, and AMPK activation helps cells adapt when energy status falls by shifting metabolism toward ATP preservation and ATP generation. That broad framework matters because AICAR is not usually studied in isolation from AMPK biology; it is studied as a way to perturb that energy-sensing network and then measure what changed. [4]

Classic and early follow-up studies explain why AICAR became entrenched in AMPK research. Corton and colleagues reported AMPK activation in intact cells after AICAR exposure, while Merrill and colleagues later described increased AMPK activity in skeletal muscle preparations together with lower acetyl-CoA carboxylase activity and downstream metabolic shifts. Those findings made AICAR useful as a pathway trigger in metabolism-focused laboratory research, but they also established an enduring limitation: downstream phenotypes need to be shown, not assumed, from the presence of AICAR alone. [3][5]

AICAR and ZMP are related but not identical

A frequent source of confusion is that researchers often discuss AICAR alongside ZMP. These are related but not identical species. AICAR is the parent nucleoside, whereas AICA ribotide, also called ZMP, is the phosphorylated monophosphate form. PubChem identifies AICA ribotide as an AMP-analog intermediate in purine biosynthesis, and the 2021 systematic review on AICAr describes ZMP as the intracellular AMP mimetic that underlies much of the canonical AMPK response ascribed to AICAR exposure. [6][7]

That distinction is not just nomenclature. Mechanistic work in vascular smooth muscle linked AICAR responses to increased ZMP and a shift in ATP/ADP ratio, reinforcing that pathway outputs depend on intracellular processing and nucleotide context rather than on the parent compound name alone. In practical terms, a research team evaluating AICAR data should always ask whether the study actually demonstrated pathway engagement or only documented compound exposure. [8]

This diagram is an editorial synthesis of mechanisms reported in the cited literature. [3][4][7][8]

What the Published Literature Actually Measures

Researchers do not usually treat AICAR itself as the endpoint. They use AICAR as an input and then measure whether AMPK-associated signals moved in a way that supports the intended mechanistic interpretation. In the strongest papers, that means proximal biochemistry first and broader biology second. The farther a readout sits from the AMPK core, the more important it becomes to show why that phenotype should still be attributed to AMPK rather than to broader nucleotide or metabolic effects. [3][5][7]

In practical reading terms, the most common proximal outputs are AMPK activity, phosphorylation-state markers linked to AMPK activation, and phosphorylation of downstream substrates such as ACC. Some studies also evaluate intracellular nucleotide context, especially when conversion to ZMP is part of the claimed mechanism. Broader phenotypes may include metabolic flux, transcriptional change, cell-state responses, or stress-signaling outputs, but those distal observations carry more interpretive risk if the paper does not anchor them back to pathway-level evidence. [4][5][7][8]

The recurring pattern across these sources is straightforward: AICAR is best understood as a pathway probe whose value depends on how tightly the study links compound exposure to proximal biochemical evidence. That is the most useful frame for both scientific reading and RUO content strategy because it keeps the article anchored to mechanism, evidence strength, and research methodology rather than to speculative outcomes. [3][5][7][8]

Why AICAR Data Can Be Misread

AICAR is widely used, but wide use is not the same as clean specificity. The 2021 AICAr systematic review and the earlier Guigas review both emphasize that AICAR can produce AMPK-dependent and AMPK-independent effects, including broader interactions with AMP-regulated enzymes and mitochondrial metabolism. That does not invalidate AICAR as a research tool, but it does mean that simplistic “AICAR equals AMPK” interpretations are weaker than the literature often suggests at first glance. [7][9]

Several mechanistic studies make that caution concrete. Rao and colleagues reported both AMPK-dependent and AMPK-independent effects for AICAR and Compound C in T-cell responses, while Hasenour and colleagues found that some AICAR-associated effects on glucose production persisted in the absence of hepatic AMPK. Those papers are especially valuable for editorial and sourcing content because they draw a clear line between pathway activation and pathway attribution. AICAR can still be informative, but it is not a universal AMPK-only switch. [10][11]

Transport adds another layer of complexity. Logie and colleagues reported that ENT1-sensitive uptake materially shaped AICAR responses in hepatocyte experiments. That means differences among laboratories may reflect transporter access and intracellular handling as much as they reflect downstream kinase biology. When studies from different systems appear inconsistent, the discrepancy may come from unequal compound entry or unequal ZMP generation rather than from contradictory AMPK biology. [12]

The practical takeaway is not that AICAR should be avoided. It is that AICAR-based conclusions are strongest when the experiment combines the compound with orthogonal confirmation such as genetic AMPK perturbation, direct downstream substrate measurement, or explicit attention to ZMP-associated nucleotide changes. That is also the most responsible way to write RUO content about the compound: present AICAR as a useful but interpretively limited research tool, not as a shortcut to broad biological claims. [7][9][10][11][12]

What to Review Before Sourcing AICAR

For procurement, begin with exact identity. The labeled material should align with accepted AICAR or acadesine naming conventions, expected small-molecule formula, and expected molecular weight, and it should be clearly distinguished from AICA ribotide or ZMP when those terms appear in supporting documentation. That naming discipline matters for AICAR more than usual because the literature ties much of the canonical mechanism to intracellular conversion, not to loose synonym use. [1][2][6]

Next, separate identity claims from purity claims. The EMA page for ICH Q2(R2) states that analytical procedures can serve different purposes, including identity, purity, impurities, assay, and other quantitative or qualitative measurements. For a research buyer, the key implication is simple: a single percentage purity statement is useful, but it is not a complete identity package by itself. A certificate of analysis is more informative when it makes clear which analytical question was actually answered. [13]

LC-MS is valuable in this context because it combines chromatographic separation with mass information, while chromatography independently supports purity and impurity profiling. In plain terms, chromatography helps show what is separated, and mass spectrometry helps show whether the detected mass is consistent with the labeled compound. For RUO AICAR procurement, that combination is more informative than an unlabeled purity figure or an undocumented identity claim. [13][14]

Practical documentation checklist

• Name and synonym alignment: AICAR, acadesine, and any lot label should describe the same parent small molecule. [1][2]
• Identity markers: the listed formula and expected molecular mass should match the labeled compound. [1][2]
• Compound-form clarity: supporting documents should not blur AICAR with AICA ribotide or ZMP. [6][7]
• Method transparency: identity and purity results are more useful when the analytical method is named and fit for purpose. [13][14]
• Batch-specific paperwork: lot-level documentation makes one batch easier to compare with another over time.
• RUO labeling: product language should remain confined to laboratory research use only.

For AICAR specifically, clarity around compound form and analytical method matters because the literature consistently ties observed pathway signals to intracellular conversion, transport context, and measurable downstream biochemistry rather than to the product name alone. That is why AICAR sourcing content should emphasize documentation quality and evidence boundaries just as strongly as the mechanism summary itself. [7][8][12][13][14]

FAQs

Is AICAR a peptide?

No. AICAR is not a peptide. PubChem indexes acadesine as the relevant compound entry, and ChEMBL classifies ACADESINE as a small molecule. That distinction matters for both scientific interpretation and supplier documentation because AICAR discussions should focus on compound identity, molecular formula, and pathway mechanism rather than peptide sequence characterization. [1][2]

Is AICAR the same as ZMP?

No, AICAR is not the same as ZMP. AICAR refers to the parent nucleoside, while ZMP refers to the phosphorylated monophosphate form, also called AICA ribotide. The distinction matters because published mechanism papers and reviews attribute much of the canonical AMPK response to intracellular ZMP rather than to the parent AICAR molecule alone. [6][7][8]

Does AICAR always indicate AMPK activation?

No, AICAR does not always justify an AMPK-specific conclusion by itself. Reviews and mechanistic papers show that AICAR can trigger AMPK-dependent and AMPK-independent effects, and some reported phenotypes persist in settings where AMPK is disrupted. For that reason, AICAR data are strongest when combined with orthogonal pathway confirmation rather than interpreted as AMPK-exclusive by default. [7][9][10][11]

Why do some papers write AICAR and others AICAr?

The literature uses both spellings, and the variation is usually nomenclature rather than a different parent compound. Database entries commonly center acadesine or AICAR, while some reviews use AICAr when discussing the riboside form in relation to the phosphorylated nucleotide. Reading the compound description closely is still important so the paper is not mistakenly interpreted as discussing ZMP itself. [1][7]

What matters most on an AICAR certificate of analysis?

The most useful AICAR certificate of analysis separates identity from purity and makes both traceable to a defined analytical method. ICH Q2(R2) treats identity, purity, impurities, and assay as different analytical purposes, and LC-MS plus chromatography can provide a more informative package than a standalone purity figure. The best COA language also aligns the lot with the correct AICAR naming and formula. [13][14][1][2]

Next Steps

Review batch-specific documentation before selecting any research-use-only compound. Explore Pure Lab Peptides for RUO peptide and research compound listings with clear labeling, research-focused product information, and available documentation.

References

1. National Center for Biotechnology Information. “Acadesine.” PubChem Compound Summary. 2026. https://pubchem.ncbi.nlm.nih.gov/compound/Acadesine
2. EMBL-EBI. “ACADESINE (CHEMBL1551724).” ChEMBL. 2026. https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1551724
3. Corton JM, Gillespie JG, Hawley SA, Hardie DG. “5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?” European Journal of Biochemistry. 1995. https://pubmed.ncbi.nlm.nih.gov/7744080/
4. Hardie DG, Ross FA, Hawley SA. “AMPK: a nutrient and energy sensor that maintains energy homeostasis.” Nature Reviews Molecular Cell Biology. 2012. https://pubmed.ncbi.nlm.nih.gov/22436748/
5. Merrill GF, Kurth EJ, Hardie DG, Winder WW. “AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle.” American Journal of Physiology-Endocrinology and Metabolism. 1997. https://doi.org/10.1152/ajpendo.1997.273.6.E1107
6. National Center for Biotechnology Information. “AICA Ribotide.” PubChem Compound Summary. 2026. https://pubchem.ncbi.nlm.nih.gov/compound/AICA-Ribotide
7. Visnjic D, Lalic H, Dembitz V, Tomic B, Smoljo T. “AICAr, a Widely Used AMPK Activator with Important AMPK-Independent Effects: A Systematic Review.” Cells. 2021. https://doi.org/10.3390/cells10051095
8. Pyla R, Hartney TJ, et al. “AICAR promotes endothelium-independent vasorelaxation by activating AMP-activated protein kinase via increased ZMP and decreased ATP/ADP ratio in aortic smooth muscle.” Journal of Basic and Clinical Physiology and Pharmacology. 2022. https://doi.org/10.1515/jbcpp-2021-0308
9. Guigas B, Sakamoto K, Taleux N, Reyna SM, Musi N, Viollet B, Hue L. “Beyond AICA riboside: In search of new specific AMP-activated protein kinase activators.” IUBMB Life. 2009. https://doi.org/10.1002/iub.135
10. Rao E, Zhang Y, Li Q, et al. “AMPK-dependent and independent effects of AICAR and Compound C on T-cell responses.” Oncotarget. 2016. https://doi.org/10.18632/oncotarget.9277
11. Hasenour CM, Ridley DE, Hughey CC, et al. “5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR) effect on glucose production, but not energy metabolism, is independent of hepatic AMPK in vivo.” Journal of Biological Chemistry. 2014. https://doi.org/10.1074/jbc.M113.528232
12. Logie L, Lees Z, Allwood JW, McDougall G, Beall C, Rena G. “Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1).” Diabetes, Obesity and Metabolism. 2018. https://doi.org/10.1111/dom.13455
13. European Medicines Agency. “ICH Q2(R2) Validation of Analytical Procedures – Scientific Guideline.” EMA. 2024. https://www.ema.europa.eu/en/ich-q2r2-validation-analytical-procedures-scientific-guideline
14. Pitt JJ. “Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry.” Clinical Biochemist Reviews. 2009. https://pubmed.ncbi.nlm.nih.gov/19224008/